Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Guardant Health Inc GH

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:GH)

Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer

Business Wire June 4, 2024

Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials

Business Wire June 3, 2024

Guardant Health Named to TIME100 Most Influential Companies

Business Wire May 31, 2024

Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening

Business Wire May 30, 2024

FDA Advisory Committee Panel Strongly Recommends Approval of Shield(TM) Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Business Wire May 23, 2024

Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening

Business Wire May 23, 2024

Guardant Health to Participate in Upcoming Investor Conferences

Business Wire May 22, 2024

Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

Business Wire May 21, 2024

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 17, 2024

Opinion & Analysis (NDAQ:GH)

No current opinion is available.

Bullboard Posts (NDAQ:GH)

Cancer Test Focused Guardant Health Stock Falls On FDA AdCom

Just In: $GH Cancer Test Focused Guardant Health Stock Falls On FDA AdCom Update For Colorectal Test | BenzingaThursday,@Guardant Health...
whytestocks - February 23, 2024

Medmira

https://finance.yahoo.com/news/medmira-announces-product-020000640.html
Rossaporino - December 31, 2020